Pharvaris (PHVS) Depreciation & Amortization (CF) (2020 - 2026)
Pharvaris (PHVS) posted Depreciation & Amortization (CF) of $122607.5 for Q1 2026, little changed on a QoQ basis from $122070.9 in Q4 2025, and up 10.69% year-over-year from $110764.5 in Q1 2025.
Pharvaris (PHVS) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Pharvaris' Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $122607.5 for Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 10.69% year-over-year to $122607.5 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $484235.0 (up 46.84% YoY) and the FY2025 annual result came in at $472659.9, up 62.0% from the prior year.
- Depreciation & Amortization (CF) was $122607.5 for Q1 2026 at Pharvaris, roughly flat from $122070.9 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $134.6 billion in Q2 2023 and bottomed at -$134.5 billion in Q3 2023.
- A 5-year average of $2.5 million and a median of $72085.5 in 2024 frame the typical range for Depreciation & Amortization (CF).
- Peak annual rise in Depreciation & Amortization (CF) reached 356841850.47% in 2023, while the deepest fall reached 345944944.87% in 2023.
- Pharvaris' Depreciation & Amortization (CF) stood at $47108.9 in 2022, then jumped by 50.8% to $71038.9 in 2023, then soared by 36.82% to $97197.3 in 2024, then rose by 25.59% to $122070.9 in 2025, then increased by 0.44% to $122607.5 in 2026.
- Business Quant data shows PHVS's Depreciation & Amortization (CF) at $122607.5 in Q1 2026, $122070.9 in Q4 2025, and $122928.5 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Pharvaris | 2.17 Bn | 1.88 Bn | - | 122,607.51 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 122,607.51 |
| Mar 31, 2026 | 122,607.51 |
| Dec 31, 2025 | 122,070.92 |
| Dec 31, 2025 | 122,070.92 |
| Sep 30, 2025 | 122,928.48 |
| Sep 30, 2025 | 122,928.48 |
| Jun 30, 2025 | 116,628.07 |
| Jun 30, 2025 | 116,628.07 |
| Mar 31, 2025 | 110,764.48 |
| Mar 31, 2025 | 110,764.48 |
| Dec 31, 2024 | 97,197.30 |
| Dec 31, 2024 | 97,197.30 |
| Sep 30, 2024 | 47,851.62 |
| Sep 30, 2024 | 47,851.62 |
| Jun 30, 2024 | 73,957.41 |
| Jun 30, 2024 | 73,957.41 |
| Mar 31, 2024 | 72,085.54 |
| Mar 31, 2024 | 72,085.54 |
| Dec 31, 2023 | 71,038.93 |
| Dec 31, 2023 | 71,038.93 |